Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22.
Blood Cancer DiscovSep 3, 2026
Clinical ResearchOncology (Medical)
Sumithira Vasu, Nathan Denlinger, No-Joon Song et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase I clinical trial evaluated the safety and efficacy of trispecific CAR T cells targeting CD19, CD20, and CD22 in 16 patients with relapsed/refractory B-cell malignancies. The study found an overall response rate of 50%, with complete responses in 83% of lymphoma patients. No severe cytokine release syndrome or neurotoxicity was reported.
Key findings
- Overall response rate was 50%, with complete responses in 83% of lymphoma patients.
- 1-year overall survival rate was 61%, indicating durable remissions.
- No severe cytokine release syndrome or neurotoxicity occurred during treatment.
- T-cell exhaustion in apheresis cells correlated with progressive disease.
Why it matters
The study highlights the potential of multispecific CAR T cell therapies to address antigen escape in B-cell malignancies, offering a promising avenue for improving patient outcomes in this challenging population.